BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84

BeOne Medicines Ltd.

2025-Q2 EPS reported $0.07 revenue$2,432,579,000

Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.
Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).
Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.
Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.